Normalization of hemoglobin level in patients with chronic kidney disease and anemia.

By T. Drüeke, F. Locatelli, N. Clyne, Kai-Uwe Eckardt, I. Macdougall, D. Tsakiris, H. Burger, A. Scherhag. New England Journal of Medicine, 2006

2,125 citations recorded by the source corpus.

Subfields: Hematology, Immunology

View Paper: https://www.semanticscholar.org/paper/ec2c2fb10ba7a37e48395388a7e91b008d17c417

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. J. Carrero
2. J. Axelsson
3. B. Lindholm
4. P. Stenvinkel
5. O. Heimbürger
6. Z. Massy

Citations in the corpus

• Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle? (2008, background): “trolled trials have consistently shown no survival benefit from multiple new treatment strategies, such as increased dialysis dose (2,3), intensified nutrition (4), homocysteine-lowering therapy (5), normalization of hemoglobin with erythropoietin (6,7), lipid lowering with statins (8), and treatmen”